. 2017 Jan 1;24(1):77–94. doi: 10.5551/jat.35626

Table 3. Serum apolipoproteins and lipid-related parameters at base and week 52 and percent changes at 52 weeks by study group.

Parameters		Combination		Fenofibrate		Ezetimibe
Parameters		n	Mean ± SD	n	Mean ± SD	n	Mean ± SD
Apo A-I (mg/dL)	Baseline	107	137 ± 18	52	134 ± 18	51	137 ± 19
	Week 52	69	144 ± 19	36	141 ± 21	38	139 ± 29
	%Change	69	7.7 ± 9.1^*	36	8.5 ± 13.1^*	38	0.9 ± 11.3
					p = 0.702		p = 0.001

Apo A-II (mg/dL)	Baseline	107	32 ± 5	52	30 ± 4	51	31 ± 4
	Week 52	69	42 ± 9	36	39 ± 10	38	31 ± 5
	%Change	69	33.7 ± 25.5^*	36	30.1 ± 29.6^*	38	−0.5 ± 9.3
					p = 0.512		p < 0.001

Apo B (mg/dL)	Baseline	107	130 ± 17	52	133 ± 20	51	134 ± 19
	Week 52	69	89 ± 19	36	105 ± 22	38	113 ± 13
	%Change	69	−31.5 ± 13.1^*	36	−21.7 ± 14.4^*	38	−15.2 ± 8.7^*
					p < 0.001		p < 0.001

Apo B-48 (µg/mL)	Baseline^a	105	11.4 ± 7.7	52	11.0 ± 7.5	50	10.0 ± 7.0
	Week 52	67	5.1 ± 3.7	35	6.8 ± 4.8	38	8.8 ± 5.1
	%Change	67	−33.7 ± 56.4^*	35	−17.9 ± 98.9	38	5.7 ± 60.4
					p = 0.305		p = 0.001

Apo C-II (mg/dL)	Baseline	107	7.0 ± 1.6	52	6.8 ± 1.8	51	7.1 ± 1.9
	Week 52	69	5.3 ± 1.7	36	5.8 ± 2.0	38	6.7 ± 1.5
	%Change	69	−20.9 ± 18.9^*	36	−15.7 ± 23.3^*	38	−0.2 ± 18.4
					p = 0.220		p < 0.001

Apo C-III (mg/dL)	Baseline	107	14.1 ± 3.2	52	13.9 ± 3.6	51	14.4 ± 3.7
	Week 52	69	9.7 ± 3.5	36	10.6 ± 3.3	38	13.8 ± 3.9
	%Change	69	−29.3 ± 18.2^*	36	−21.8 ± 24.7^*	38	−2.2 ± 25.3
					p = 0.081		p < 0.001

Apo E (mg/dL)	Baseline	107	5.2 ± 1.1	52	5.1 ± 1.2	51	5.2 ± 1.4
	Week 52	69	3.8 ± 0.9	36	4.1 ± 0.8	38	4.7 ± 1.5
	%Change	69	−24.1 ± 15.4^*	36	−18.3 ± 21.0^*	38	−6.9 ± 18.2^*
					p = 0.111		p < 0.001

RemL-C (mg/dL)	Baseline^a	105	19.7 ± 11.0	52	20.2 ± 14.9	50	20.8 ± 21.5
	Week 52	69	8.3 ± 5.1	36	12.1 ± 7.2	38	16.3 ± 6.1
	%Change	69	−46.1 ± 37.3^*	36	−17.4 ± 93.1	38	−3.2 ± 38.8
					p = 0.026		p < 0.001

LDL particle size	Baseline^a	105	25.9 ± 0.6	52	25.9 ± 0.8	49	25.8 ± 0.6
(nm)	Week 52	69	26.7 ± 0.6	36	26.6 ± 0.6	38	25.9 ± 0.6
	%Change	69	3.4 ± 2.9^*	36	3.4 ± 2.8^*	38	0.5 ± 2.2
					p = 0.996		p < 0.001

HDL particle size	Baseline^a	105	10.5 ± 0.3	52	10.5 ± 0.3	49	10.5 ± 0.3
(nm)	Week 52	69	10.4 ± 0.2	36	10.4 ± 0.2	38	10.5 ± 0.3
	%Change	69	−0.9 ± 1.8^*	36	−0.7 ± 1.5^*	38	0.4 ± 1.7
					p = 0.712		p < 0.001

Phospholipid	Baseline^a	95	349 ± 282	47	320 ± 217	45	313 ± 449
hydroperoxide	Week 52	69	294 ± 236	36	261 ± 224	37	264 ± 226
(nmol/L)	%Change	60	−0.9 ± 48.1	31	−11.1 ± 34.1	33	9.0 ± 49.9
					p = 0.294		p = 0.352

hsCRP (mg/dL)	Baseline^a	105	0.16 ± 0.21	52	0.15 ± 0.20	50	0.19 ± 0.23
	Week 52	69	0.13 ± 0.18	36	0.09 ± 0.13	38	0.19 ± 0.22
	%Change	69	30.3 ± 264.0	36	−3.0 ± 78.4	38	123.9 ± 406.3
					p = 0.462		p = 0.152

Mean values at baseline were based on the average of multiple measurements during the pretreatment period (week −4 to week 0)

p values represent the comparison of the percent changes between the combination group and the specified group by two-sample t-test (two-sided).

A single measurement at week 0

p < 0.05 for the within-group comparison by one sample t-test.

Apo, apolipoprotein; RemL-C, remnant-like lipoprotein cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hsCRP high-sensitivity assay for C-reactive protein